TY - JOUR
T1 - Hepatitis B Virus Reactivation Potentiated by Biologics
AU - Ogawa, Eiichi
AU - Wei, Mike T.
AU - Nguyen, Mindie H.
N1 - Funding Information:
M.H. Nguyen: Grant/research support: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceutical; Advisory board/consultant: Dynavax Laboratories, Gilead Sciences, Intercept Pharmaceutical; Anylam Pharmaceutical; Roche Laboratories; and Novartis Pharmaceuticals. The other authors have nothing to disclose.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6
Y1 - 2020/6
N2 - Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
AB - Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics. For HBsAg-positive patients receiving biologics, the risk of HBV reactivation is moderate to high. HBsAg-negative/anti-HBc positive patients are at lower risk of HBV reactivation than HBsAg-positive patients. However, patients taking anti-CD20 agents, such as rituximab, have high risk of HBV reactivation (>10%), so antiviral prophylactic therapies are required. This review provides the different classes of biologics associated with HBV reactivation, stratifies the various reactivation risk levels by HBV status and biologic agent, and discusses management strategies.
UR - http://www.scopus.com/inward/record.url?scp=85083489013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083489013&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2020.02.009
DO - 10.1016/j.idc.2020.02.009
M3 - Review article
C2 - 32334985
AN - SCOPUS:85083489013
SN - 0891-5520
VL - 34
SP - 341
EP - 358
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
IS - 2
ER -
